May 16, 2024 10:44 AM EDT
News Briefing

Monte Rosa’s $100M of­fer­ing; Alex­ion to hand back pre­clin­i­cal pro­gram to Zealand Phar­ma

ENDPOINTS

Plus, news about First Wave Bio­Phar­ma:

Monte Rosa’s $100M of­fer­ing: The mol­e­c­u­lar glue de­grad­er biotech priced the of­fer­ing at $4.70 per …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times